#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-11	Eveningness	_
1-2	12-17	among	_
1-3	18-22	late	_
1-4	23-33	adolescent	_
1-5	34-39	males	_
1-6	40-48	predicts	_
1-7	49-55	neural	_
1-8	56-66	reactivity	_
1-9	67-69	to	_
1-10	70-76	reward	_
1-11	77-80	and	_
1-12	81-88	alcohol	_
1-13	89-99	dependence	_
1-14	100-103	two	_
1-15	104-109	years	_
1-16	110-115	later	_
1-17	116-127	Eveningness	_
1-18	128-129	,	_
1-19	130-131	a	_
1-20	132-142	preference	_
1-21	143-146	for	_
1-22	147-152	later	_
1-23	153-163	sleep-wake	_
1-24	164-170	timing	_
1-25	171-172	,	_
1-26	173-175	is	_
1-27	176-182	linked	_
1-28	183-185	to	_
1-29	186-193	altered	_
1-30	194-200	reward	_
1-31	201-209	function	_
1-32	210-211	,	_
1-33	212-217	which	_
1-34	218-221	may	_
1-35	222-229	explain	_
1-36	230-231	a	_
1-37	232-242	consistent	_
1-38	243-254	association	_
1-39	255-259	with	_
1-40	260-269	substance	_
1-41	270-275	abuse	_
1-42	276-277	.	_

2-1	278-285	Notably	_
2-2	286-287	,	_
2-3	288-291	the	_
2-4	292-298	extant	_
2-5	299-309	literature	_
2-6	310-315	rests	_
2-7	316-323	largely	_
2-8	324-326	on	_
2-9	327-342	cross-sectional	_
2-10	343-347	data	_
2-11	348-349	,	_
2-12	350-353	yet	_
2-13	354-358	both	_
2-14	359-370	eveningness	_
2-15	371-374	and	_
2-16	375-381	reward	_
2-17	382-390	function	_
2-18	391-395	show	_
2-19	396-409	developmental	_
2-20	410-417	changes	_
2-21	418-419	.	_

3-1	420-422	We	_
3-2	423-431	examined	_
3-3	432-439	whether	_
3-4	440-449	circadian	_
3-5	450-460	preference	_
3-6	461-467	during	_
3-7	468-472	late	_
3-8	473-484	adolescence	_
3-9	485-494	predicted	_
3-10	495-498	the	_
3-11	499-505	neural	_
3-12	506-514	response	_
3-13	515-517	to	_
3-14	518-524	reward	_
3-15	525-528	two	_
3-16	529-534	years	_
3-17	535-540	later	_
3-18	541-542	.	_

4-1	543-544	A	_
4-2	545-551	sample	_
4-3	552-554	of	_
4-4	555-557	93	_
4-5	558-563	males	_
4-6	564-572	reported	_
4-7	573-582	circadian	_
4-8	583-593	preference	_
4-9	594-597	and	_
4-10	598-607	completed	_
4-11	608-609	a	_
4-12	610-618	monetary	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol
4-13	619-625	reward	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol
4-14	626-630	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol
4-15	631-639	paradigm	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImagingProtocol
4-16	640-642	at	_
4-17	643-647	ages	_
4-18	648-650	20	_
4-19	651-654	and	_
4-20	655-657	22	_
4-21	658-659	.	_

5-1	660-667	Primary	_
5-2	668-676	analyses	_
5-3	677-685	examined	_
5-4	686-698	longitudinal	_
5-5	699-704	paths	_
5-6	705-709	from	_
5-7	710-719	circadian	_
5-8	720-730	preference	_
5-9	731-733	to	_
5-10	734-740	medial	_
5-11	741-751	prefrontal	_
5-12	752-758	cortex	_
5-13	759-760	(	_
5-14	761-765	mPFC	_
5-15	766-767	)	_
5-16	768-771	and	_
5-17	772-779	ventral	_
5-18	780-788	striatal	_
5-19	789-790	(	_
5-20	791-793	VS	_
5-21	794-795	)	_
5-22	796-802	reward	_
5-23	803-812	responses	_
5-24	813-814	.	_

6-1	815-817	We	_
6-2	818-822	also	_
6-3	823-831	explored	_
6-4	832-839	whether	_
6-5	840-846	reward	_
6-6	847-856	responses	_
6-7	857-865	mediated	_
6-8	866-878	longitudinal	_
6-9	879-891	associations	_
6-10	892-899	between	_
6-11	900-909	circadian	_
6-12	910-920	preference	_
6-13	921-924	and	_
6-14	925-932	alcohol	_
6-15	933-943	dependence	_
6-16	944-945	,	_
6-17	946-955	frequency	_
6-18	956-958	of	_
6-19	959-966	alcohol	_
6-20	967-970	use	_
6-21	971-972	,	_
6-22	973-979	and/or	_
6-23	980-989	frequency	_
6-24	990-992	of	_
6-25	993-1001	cannabis	_
6-26	1002-1005	use	_
6-27	1006-1007	.	_

7-1	1008-1011	Age	_
7-2	1012-1014	20	_
7-3	1015-1026	eveningness	_
7-4	1027-1030	was	_
7-5	1031-1041	positively	_
7-6	1042-1052	associated	_
7-7	1053-1057	with	_
7-8	1058-1061	age	_
7-9	1062-1064	22	_
7-10	1065-1069	mPFC	_
7-11	1070-1073	and	_
7-12	1074-1076	VS	_
7-13	1077-1086	responses	_
7-14	1087-1089	to	_
7-15	1090-1093	win	_
7-16	1094-1095	,	_
7-17	1096-1099	but	_
7-18	1100-1103	not	_
7-19	1104-1114	associated	_
7-20	1115-1119	with	_
7-21	1120-1123	age	_
7-22	1124-1126	22	_
7-23	1127-1137	reactivity	_
7-24	1138-1140	to	_
7-25	1141-1147	reward	_
7-26	1148-1160	anticipation	_
7-27	1161-1162	.	_

8-1	1163-1166	Age	_
8-2	1167-1169	20	_
8-3	1170-1181	eveningness	_
8-4	1182-1185	was	_
8-5	1186-1196	indirectly	_
8-6	1197-1204	related	_
8-7	1205-1207	to	_
8-8	1208-1211	age	_
8-9	1212-1214	22	_
8-10	1215-1222	alcohol	_
8-11	1223-1233	dependence	_
8-12	1234-1237	via	_
8-13	1238-1241	age	_
8-14	1242-1244	22	_
8-15	1245-1249	mPFC	_
8-16	1250-1258	response	_
8-17	1259-1261	to	_
8-18	1262-1265	win	_
8-19	1266-1267	.	_

9-1	1268-1271	Our	_
9-2	1272-1280	findings	_
9-3	1281-1288	provide	_
9-4	1289-1294	novel	_
9-5	1295-1303	evidence	_
9-6	1304-1308	that	_
9-7	1309-1316	altered	_
9-8	1317-1331	reward-related	_
9-9	1332-1337	brain	_
9-10	1338-1346	function	_
9-11	1347-1352	could	_
9-12	1353-1361	underlie	_
9-13	1362-1374	associations	_
9-14	1375-1382	between	_
9-15	1383-1394	eveningness	_
9-16	1395-1398	and	_
9-17	1399-1406	alcohol	_
9-18	1407-1410	use	_
9-19	1411-1419	problems	_
9-20	1420-1421	.	_

10-1	1422-1433	Eveningness	_
10-2	1434-1437	may	_
10-3	1438-1440	be	_
10-4	1441-1443	an	_
10-5	1444-1460	under-recognized	_
10-6	1461-1464	but	_
10-7	1465-1475	modifiable	_
10-8	1476-1480	risk	_
10-9	1481-1487	factor	_
10-10	1488-1491	for	_
10-11	1492-1506	reward-related	_
10-12	1507-1515	problems	_
10-13	1516-1520	such	_
10-14	1521-1523	as	_
10-15	1524-1528	mood	_
10-16	1529-1532	and	_
10-17	1533-1542	substance	_
10-18	1543-1546	use	_
10-19	1547-1556	disorders	_
10-20	1557-1558	.	_

11-1	1559-1560	2	_
11-2	1561-1562	.	_

12-1	1563-1570	METHODS	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-2	1571-1574	AND	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-3	1575-1584	MATERIALS	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-4	1585-1588	2.1	_
12-5	1589-1601	Participants	_
12-6	1602-1614	Participants	_
12-7	1615-1619	were	_
12-8	1620-1625	drawn	_
12-9	1626-1630	from	_
12-10	1631-1634	the	_
12-11	1635-1639	Pitt	http://maven.renci.org/NeuroBridge/neurobridge#PittsburghSleepQualityIndex
12-12	1640-1646	Mother	_
12-13	1647-1648	&	_
12-14	1649-1654	Child	_
12-15	1655-1662	Project	_
12-16	1663-1664	(	_
12-17	1665-1669	PMCP	_
12-18	1670-1671	)	_
12-19	1672-1673	,	_
12-20	1674-1676	an	_
12-21	1677-1684	ongoing	_
12-22	1685-1697	longitudinal	_
12-23	1698-1703	study	_
12-24	1704-1713	examining	_
12-25	1714-1727	vulnerability	_
12-26	1728-1731	and	_
12-27	1732-1742	resilience	_
12-28	1743-1745	in	_
12-29	1746-1756	low-income	http://maven.renci.org/NeuroBridge/neurobridge#LowRisk
12-30	1757-1761	boys	http://maven.renci.org/NeuroBridge/neurobridge#LowRisk
12-31	1762-1763	.	_

13-1	1764-1767	The	_
13-2	1768-1775	initial	_
13-3	1776-1782	sample	_
13-4	1783-1792	consisted	_
13-5	1793-1795	of	_
13-6	1796-1799	310	_
13-7	1800-1804	boys	_
13-8	1805-1808	and	_
13-9	1809-1814	their	_
13-10	1815-1823	families	_
13-11	1824-1825	,	_
13-12	1826-1835	recruited	_
13-13	1836-1840	when	_
13-14	1841-1845	boys	_
13-15	1846-1850	were	_
13-16	1851-1852	6	_
13-17	1853-1855	to	_
13-18	1856-1858	17	_
13-19	1859-1865	months	_
13-20	1866-1869	old	_
13-21	1870-1877	through	_
13-22	1878-1883	Women	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
13-23	1884-1885	,	_
13-24	1886-1893	Infants	http://maven.renci.org/NeuroBridge/neurobridge#NutritionQuestionnaire
13-25	1894-1895	,	http://maven.renci.org/NeuroBridge/neurobridge#NutritionQuestionnaire
13-26	1896-1899	and	http://maven.renci.org/NeuroBridge/neurobridge#NutritionQuestionnaire
13-27	1900-1908	Children	http://maven.renci.org/NeuroBridge/neurobridge#NutritionQuestionnaire
13-28	1909-1920	Nutritional	http://maven.renci.org/NeuroBridge/neurobridge#NutritionQuestionnaire
13-29	1921-1931	Supplement	http://maven.renci.org/NeuroBridge/neurobridge#NutritionQuestionnaire
13-30	1932-1933	(	http://maven.renci.org/NeuroBridge/neurobridge#NutritionQuestionnaire
13-31	1934-1937	WIC	_
13-32	1938-1939	)	_
13-33	1940-1948	programs	_
13-34	1949-1956	serving	_
13-35	1957-1967	low-income	_
13-36	1968-1976	families	_
13-37	1977-1979	in	_
13-38	1980-1983	the	_
13-39	1984-1994	Pittsburgh	_
13-40	1995-2007	metropolitan	_
13-41	2008-2012	area	_
13-42	2013-2014	(	_
13-43	2015-2018	see	_
13-44	2019-2020	.	_

14-1	2021-2024	The	_
14-2	2025-2032	current	_
14-3	2033-2038	study	_
14-4	2039-2047	utilizes	_
14-5	2048-2052	data	_
14-6	2053-2057	from	_
14-7	2058-2068	subsequent	_
14-8	2069-2079	laboratory	_
14-9	2080-2086	visits	_
14-10	2087-2091	when	_
14-11	2092-2104	participants	_
14-12	2105-2109	were	_
14-13	2110-2112	20	_
14-14	2113-2116	and	_
14-15	2117-2119	22	_
14-16	2120-2125	years	_
14-17	2126-2128	of	_
14-18	2129-2132	age	_
14-19	2133-2134	.	_

15-1	2135-2140	These	_
15-2	2141-2147	visits	_
15-3	2148-2152	each	_
15-4	2153-2161	included	_
15-5	2162-2163	a	_
15-6	2164-2172	clinical	_
15-7	2173-2182	interview	_
15-8	2183-2184	,	_
15-9	2185-2196	self-report	_
15-10	2197-2205	measures	_
15-11	2206-2207	,	_
15-12	2208-2211	and	_
15-13	2212-2214	an	_
15-14	2215-2219	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
15-15	2220-2224	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
15-16	2225-2226	.	_

16-1	2227-2234	Written	_
16-2	2235-2243	informed	_
16-3	2244-2251	consent	_
16-4	2252-2255	was	_
16-5	2256-2264	obtained	_
16-6	2265-2268	for	_
16-7	2269-2272	all	_
16-8	2273-2285	participants	_
16-9	2286-2287	.	_

17-1	2288-2291	The	_
17-2	2292-2297	study	_
17-3	2298-2301	was	_
17-4	2302-2310	approved	_
17-5	2311-2313	by	_
17-6	2314-2317	the	_
17-7	2318-2331	Institutional	_
17-8	2332-2338	Review	_
17-9	2339-2344	Board	_
17-10	2345-2347	of	_
17-11	2348-2351	the	_
17-12	2352-2362	University	_
17-13	2363-2365	of	_
17-14	2366-2376	Pittsburgh	_
17-15	2377-2378	.	_

18-1	2379-2391	Participants	_
18-2	2392-2396	were	_
18-3	2397-2402	asked	_
18-4	2403-2405	to	_
18-5	2406-2413	refrain	_
18-6	2414-2418	from	_
18-7	2419-2424	using	_
18-8	2425-2428	any	_
18-9	2429-2436	illegal	_
18-10	2437-2447	substances	_
18-11	2448-2456	starting	_
18-12	2457-2459	48	_
18-13	2460-2461	h	_
18-14	2462-2467	prior	_
18-15	2468-2470	to	_
18-16	2471-2476	their	_
18-17	2477-2481	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
18-18	2482-2486	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
18-19	2487-2490	and	_
18-20	2491-2494	all	_
18-21	2495-2507	participants	_
18-22	2508-2512	were	_
18-23	2513-2521	approved	_
18-24	2522-2525	for	_
18-25	2526-2529	the	_
18-26	2530-2534	scan	_
18-27	2535-2537	by	_
18-28	2538-2539	a	_
18-29	2540-2550	registered	_
18-30	2551-2556	nurse	_
18-31	2557-2558	.	_

19-1	2559-2560	A	_
19-2	2561-2572	combination	_
19-3	2573-2575	of	_
19-4	2576-2588	breathalyzer	_
19-5	2589-2590	,	_
19-6	2591-2597	saliva	_
19-7	2598-2602	drug	_
19-8	2603-2609	screen	_
19-9	2610-2611	,	_
19-10	2612-2623	self-report	_
19-11	2624-2625	,	_
19-12	2626-2629	and	_
19-13	2630-2638	clinical	_
19-14	2639-2647	judgment	_
19-15	2648-2652	were	_
19-16	2653-2657	used	_
19-17	2658-2660	to	_
19-18	2661-2670	determine	_
19-19	2671-2676	which	_
19-20	2677-2689	participants	_
19-21	2690-2694	were	_
19-22	2695-2703	approved	_
19-23	2704-2706	to	_
19-24	2707-2711	scan	_
19-25	2712-2713	.	_

20-1	2714-2715	A	_
20-2	2716-2721	total	_
20-3	2722-2724	of	_
20-4	2725-2728	106	_
20-5	2729-2741	participants	_
20-6	2742-2745	had	_
20-7	2746-2755	circadian	_
20-8	2756-2766	preference	_
20-9	2767-2771	data	_
20-10	2772-2774	at	_
20-11	2775-2779	both	_
20-12	2780-2783	age	_
20-13	2784-2786	20	_
20-14	2787-2790	and	_
20-15	2791-2793	22	_
20-16	2794-2795	.	_

21-1	2796-2798	Of	_
21-2	2799-2804	these	_
21-3	2805-2806	,	_
21-4	2807-2808	a	_
21-5	2809-2814	total	_
21-6	2815-2817	of	_
21-7	2818-2820	93	_
21-8	2821-2833	participants	_
21-9	2834-2837	had	_
21-10	2838-2843	valid	_
21-11	2844-2850	reward	_
21-12	2851-2855	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
21-13	2856-2860	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
21-14	2861-2865	data	_
21-15	2866-2868	at	_
21-16	2869-2873	both	_
21-17	2874-2878	ages	_
21-18	2879-2880	(	_
21-19	2881-2882	5	_
21-20	2883-2887	were	_
21-21	2888-2896	excluded	_
21-22	2897-2904	because	_
21-23	2905-2907	of	_
21-24	2908-2918	scheduling	_
21-25	2919-2930	limitations	_
21-26	2931-2932	,	_
21-27	2933-2934	2	_
21-28	2935-2939	were	_
21-29	2940-2948	excluded	_
21-30	2949-2956	because	_
21-31	2957-2959	of	_
21-32	2960-2974	claustrophobia	_
21-33	2975-2976	,	_
21-34	2977-2978	2	_
21-35	2979-2983	were	_
21-36	2984-2992	excluded	_
21-37	2993-3000	because	_
21-38	3001-3003	of	_
21-39	3004-3016	metal/bullet	_
21-40	3017-3026	fragments	_
21-41	3027-3028	,	_
21-42	3029-3030	2	_
21-43	3031-3035	were	_
21-44	3036-3044	excluded	_
21-45	3045-3052	because	_
21-46	3053-3055	of	_
21-47	3056-3066	inadequate	_
21-48	3067-3075	coverage	_
21-49	3076-3078	of	_
21-50	3079-3082	the	_
21-51	3083-3090	ventral	_
21-52	3091-3099	striatum	_
21-53	3100-3101	,	_
21-54	3102-3103	1	_
21-55	3104-3107	was	_
21-56	3108-3116	excluded	_
21-57	3117-3124	because	_
21-58	3125-3127	of	_
21-59	3128-3144	misunderstanding	_
21-60	3145-3148	the	_
21-61	3149-3153	task	_
21-62	3154-3155	,	_
21-63	3156-3159	and	_
21-64	3160-3161	1	_
21-65	3162-3169	refused	_
21-66	3170-3173	the	_
21-67	3174-3178	scan	_
21-68	3179-3180	)	_
21-69	3181-3182	.	_

22-1	3183-3186	2.2	_
22-2	3187-3195	Clinical	_
22-3	3196-3204	measures	_
22-4	3205-3214	Circadian	_
22-5	3215-3225	preference	_
22-6	3226-3228	We	_
22-7	3229-3233	used	_
22-8	3234-3237	the	_
22-9	3238-3247	Composite	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale
22-10	3248-3253	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale
22-11	3254-3256	of	http://maven.renci.org/NeuroBridge/neurobridge#PsychopathologyScale
22-12	3257-3268	Morningness	_
22-13	3269-3271	to	_
22-14	3272-3278	assess	_
22-15	3279-3288	circadian	_
22-16	3289-3299	preference	_
22-17	3300-3302	at	_
22-18	3303-3306	the	_
22-19	3307-3310	age	_
22-20	3311-3313	20	_
22-21	3314-3317	and	_
22-22	3318-3320	22	_
22-23	3321-3332	assessments	_
22-24	3333-3334	(	_
22-25	3335-3338	age	_
22-26	3339-3341	20	_
22-27	3342-3348	α=0.63	_
22-28	3349-3350	;	_
22-29	3351-3354	age	_
22-30	3355-3357	22	_
22-31	3358-3364	α=0.65	_
22-32	3365-3366	)	_
22-33	3367-3368	.	_

23-1	3369-3372	The	_
23-2	3373-3378	score	_
23-3	3379-3381	is	_
23-4	3382-3390	obtained	_
23-5	3391-3393	by	_
23-6	3394-3397	the	_
23-7	3398-3401	sum	_
23-8	3402-3404	of	_
23-9	3405-3407	13	_
23-10	3408-3419	Likert-type	_
23-11	3420-3425	items	_
23-12	3426-3427	,	_
23-13	3428-3431	and	_
23-14	3432-3438	ranges	_
23-15	3439-3443	from	_
23-16	3444-3446	13	_
23-17	3447-3448	(	_
23-18	3449-3456	extreme	_
23-19	3457-3468	eveningness	_
23-20	3469-3470	)	_
23-21	3471-3473	to	_
23-22	3474-3476	55	_
23-23	3477-3478	(	_
23-24	3479-3486	extreme	_
23-25	3487-3498	morningness	_
23-26	3499-3500	)	_
23-27	3501-3502	.	_

24-1	3503-3511	Although	_
24-2	3512-3514	we	_
24-3	3515-3519	used	_
24-4	3520-3523	the	_
24-5	3524-3527	CSM	_
24-6	3528-3533	score	_
24-7	3534-3536	as	_
24-8	3537-3538	a	_
24-9	3539-3549	continuous	_
24-10	3550-3557	measure	_
24-11	3558-3561	for	_
24-12	3562-3565	the	_
24-13	3566-3573	primary	_
24-14	3574-3582	analyses	_
24-15	3583-3584	,	_
24-16	3585-3588	for	_
24-17	3589-3600	descriptive	_
24-18	3601-3609	purposes	_
24-19	3610-3612	we	_
24-20	3613-3617	also	_
24-21	3618-3628	classified	_
24-22	3629-3641	participants	_
24-23	3642-3644	by	_
24-24	3645-3649	type	_
24-25	3650-3655	using	_
24-26	3656-3659	the	_
24-27	3660-3667	scoring	_
24-28	3668-3678	thresholds	_
24-29	3679-3688	suggested	_
24-30	3689-3691	by	_
24-31	3692-3698	Natale	_
24-32	3699-3702	and	_
24-33	3703-3709	Alzani	_
24-34	3710-3711	:	_
24-35	3712-3730	13–26=evening-type	_
24-36	3731-3732	;	_
24-37	3733-3756	27–41=intermediate-type	_
24-38	3757-3758	;	_
24-39	3759-3777	42–55=morning-type	_
24-40	3778-3779	.	_

25-1	3780-3787	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
25-2	3788-3798	dependence	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
25-3	3799-3801	We	_
25-4	3802-3806	used	_
25-5	3807-3810	the	_
25-6	3811-3814	age	_
25-7	3815-3817	22	_
25-8	3818-3832	administration	_
25-9	3833-3835	of	_
25-10	3836-3839	the	_
25-11	3840-3847	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
25-12	3848-3858	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
25-13	3859-3864	Scale	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
25-14	3865-3866	(	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
25-15	3867-3870	ADS	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
25-16	3871-3872	)	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
25-17	3873-3874	,	_
25-18	3875-3876	a	_
25-19	3877-3884	25-item	_
25-20	3885-3898	questionnaire	_
25-21	3899-3901	to	_
25-22	3902-3908	assess	_
25-23	3909-3922	self-reported	_
25-24	3923-3930	alcohol	_
25-25	3931-3941	withdrawal	_
25-26	3942-3950	symptoms	_
25-27	3951-3952	,	_
25-28	3953-3961	impaired	_
25-29	3962-3969	control	_
25-30	3970-3974	over	_
25-31	3975-3983	drinking	_
25-32	3984-3985	,	_
25-33	3986-3995	awareness	_
25-34	3996-3998	of	_
25-35	3999-4000	a	_
25-36	4001-4011	compulsion	_
25-37	4012-4014	to	_
25-38	4015-4020	drink	_
25-39	4021-4022	,	_
25-40	4023-4032	increased	_
25-41	4033-4042	tolerance	_
25-42	4043-4045	to	_
25-43	4046-4053	alcohol	_
25-44	4054-4055	,	_
25-45	4056-4059	and	_
25-46	4060-4068	salience	_
25-47	4069-4071	of	_
25-48	4072-4085	drink-seeking	_
25-49	4086-4094	behavior	_
25-50	4095-4097	in	_
25-51	4098-4101	the	_
25-52	4102-4106	past	_
25-53	4107-4111	year	_
25-54	4112-4113	.	_

26-1	4114-4115	A	_
26-2	4116-4121	score	_
26-3	4122-4124	of	_
26-4	4125-4126	9	_
26-5	4127-4129	or	_
26-6	4130-4134	more	_
26-7	4135-4137	is	_
26-8	4138-4144	highly	_
26-9	4145-4155	indicative	_
26-10	4156-4158	of	_
26-11	4159-4166	current	_
26-12	4167-4176	diagnosis	_
26-13	4177-4179	of	_
26-14	4180-4187	alcohol	_
26-15	4188-4193	abuse	_
26-16	4194-4196	or	_
26-17	4197-4207	dependence	_
26-18	4208-4209	(	_
26-19	4210-4216	α=0.78	_
26-20	4217-4220	for	_
26-21	4221-4227	sample	_
26-22	4228-4229	)	_
26-23	4230-4231	.	_

27-1	4232-4239	Because	_
27-2	4240-4243	the	_
27-3	4244-4247	ADS	_
27-4	4248-4251	was	_
27-5	4252-4264	administered	_
27-6	4265-4269	only	_
27-7	4270-4272	to	_
27-8	4273-4285	participants	_
27-9	4286-4295	reporting	_
27-10	4296-4303	current	_
27-11	4304-4311	alcohol	_
27-12	4312-4315	use	_
27-13	4316-4318	at	_
27-14	4319-4322	age	_
27-15	4323-4325	20	_
27-16	4326-4327	(	_
27-17	4328-4332	n=70	_
27-18	4333-4335	in	_
27-19	4336-4339	the	_
27-20	4340-4347	present	_
27-21	4348-4354	sample	_
27-22	4355-4356	)	_
27-23	4357-4358	,	_
27-24	4359-4361	we	_
27-25	4362-4369	elected	_
27-26	4370-4372	to	_
27-27	4373-4378	focus	_
27-28	4379-4383	only	_
27-29	4384-4386	on	_
27-30	4387-4390	age	_
27-31	4391-4393	22	_
27-32	4394-4397	ADS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
27-33	4398-4404	scores	_
27-34	4405-4407	in	_
27-35	4408-4411	the	_
27-36	4412-4419	primary	_
27-37	4420-4428	analyses	_
27-38	4429-4430	.	_

28-1	4431-4438	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
28-2	4439-4442	use	_
28-3	4443-4445	We	_
28-4	4446-4454	assessed	_
28-5	4455-4464	frequency	_
28-6	4465-4467	of	_
28-7	4468-4475	alcohol	_
28-8	4476-4479	use	_
28-9	4480-4483	via	_
28-10	4484-4487	the	_
28-11	4488-4491	age	_
28-12	4492-4494	20	_
28-13	4495-4498	and	_
28-14	4499-4501	22	_
28-15	4502-4517	administrations	_
28-16	4518-4520	of	_
28-17	4521-4524	the	_
28-18	4525-4533	Lifetime	_
28-19	4534-4542	Drinking	_
28-20	4543-4550	History	_
28-21	4551-4552	,	_
28-22	4553-4554	a	_
28-23	4555-4565	structured	_
28-24	4566-4575	interview	_
28-25	4576-4584	designed	_
28-26	4585-4587	to	_
28-27	4588-4596	quantify	_
28-28	4597-4605	lifetime	_
28-29	4606-4614	patterns	_
28-30	4615-4617	of	_
28-31	4618-4621	the	_
28-32	4622-4625	use	_
28-33	4626-4628	of	_
28-34	4629-4636	alcohol	_
28-35	4637-4638	.	_

29-1	4639-4651	Participants	_
29-2	4652-4660	reported	_
29-3	4661-4663	on	_
29-4	4664-4668	past	_
29-5	4669-4673	year	_
29-6	4674-4683	frequency	_
29-7	4684-4686	of	_
29-8	4687-4694	alcohol	_
29-9	4695-4696	(	_
29-10	4697-4701	days	_
29-11	4702-4705	per	_
29-12	4706-4711	month	_
29-13	4712-4713	)	_
29-14	4714-4715	.	_

30-1	4716-4721	Based	_
30-2	4722-4724	on	_
30-3	4725-4728	the	_
30-4	4729-4735	skewed	_
30-5	4736-4748	distribution	_
30-6	4749-4751	of	_
30-7	4752-4759	alcohol	_
30-8	4760-4763	use	_
30-9	4764-4768	data	_
30-10	4769-4770	,	_
30-11	4771-4773	we	_
30-12	4774-4778	used	_
30-13	4779-4780	a	_
30-14	4781-4792	square-root	_
30-15	4793-4807	transformation	_
30-16	4808-4809	.	_

31-1	4810-4818	Cannabis	_
31-2	4819-4822	use	_
31-3	4823-4831	Although	_
31-4	4832-4834	we	_
31-5	4835-4838	did	_
31-6	4839-4842	not	_
31-7	4843-4847	have	_
31-8	4848-4849	a	_
31-9	4850-4857	measure	_
31-10	4858-4860	of	_
31-11	4861-4869	cannabis	_
31-12	4870-4878	problems	_
31-13	4879-4887	parallel	_
31-14	4888-4890	to	_
31-15	4891-4894	the	_
31-16	4895-4898	ADS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
31-17	4899-4900	,	_
31-18	4901-4903	we	_
31-19	4904-4912	assessed	_
31-20	4913-4922	frequency	_
31-21	4923-4925	of	_
31-22	4926-4934	cannabis	_
31-23	4935-4938	use	_
31-24	4939-4942	via	_
31-25	4943-4946	the	_
31-26	4947-4950	age	_
31-27	4951-4953	20	_
31-28	4954-4957	and	_
31-29	4958-4960	22	_
31-30	4961-4976	administrations	_
31-31	4977-4979	of	_
31-32	4980-4983	the	_
31-33	4984-4992	Lifetime	_
31-34	4993-4997	Drug	_
31-35	4998-5001	Use	_
31-36	5002-5009	History	_
31-37	5010-5011	,	_
31-38	5012-5013	a	_
31-39	5014-5024	structured	_
31-40	5025-5034	interview	_
31-41	5035-5043	designed	_
31-42	5044-5046	to	_
31-43	5047-5055	quantify	_
31-44	5056-5064	lifetime	_
31-45	5065-5073	patterns	_
31-46	5074-5076	of	_
31-47	5077-5080	the	_
31-48	5081-5084	use	_
31-49	5085-5087	of	_
31-50	5088-5095	various	_
31-51	5096-5106	substances	_
31-52	5107-5108	.	_

32-1	5109-5121	Participants	_
32-2	5122-5130	reported	_
32-3	5131-5133	on	_
32-4	5134-5138	past	_
32-5	5139-5143	year	_
32-6	5144-5153	frequency	_
32-7	5154-5156	of	_
32-8	5157-5165	cannabis	_
32-9	5166-5169	use	_
32-10	5170-5171	(	_
32-11	5172-5176	days	_
32-12	5177-5180	per	_
32-13	5181-5186	month	_
32-14	5187-5188	)	_
32-15	5189-5190	.	_

33-1	5191-5196	Based	_
33-2	5197-5199	on	_
33-3	5200-5203	the	_
33-4	5204-5211	bimodal	_
33-5	5212-5224	distribution	_
33-6	5225-5227	of	_
33-7	5228-5231	the	_
33-8	5232-5240	cannabis	_
33-9	5241-5244	use	_
33-10	5245-5249	data	_
33-11	5250-5251	,	_
33-12	5252-5254	we	_
33-13	5255-5262	created	_
33-14	5263-5265	an	_
33-15	5266-5273	ordinal	_
33-16	5274-5281	version	_
33-17	5282-5284	of	_
33-18	5285-5288	the	_
33-19	5289-5297	variable	_
33-20	5298-5299	(	_
33-21	5300-5304	0=no	_
33-22	5305-5309	days	_
33-23	5310-5313	per	_
33-24	5314-5319	month	_
33-25	5320-5321	,	_
33-26	5322-5328	1=1–19	_
33-27	5329-5333	days	_
33-28	5334-5337	per	_
33-29	5338-5343	month	_
33-30	5344-5345	,	_
33-31	5346-5351	3=20+	_
33-32	5352-5356	days	_
33-33	5357-5360	per	_
33-34	5361-5366	month	_
33-35	5367-5368	)	_
33-36	5369-5373	with	_
33-37	5374-5375	a	_
33-38	5376-5384	unimodal	_
33-39	5385-5397	distribution	_
33-40	5398-5399	(	_
33-41	5400-5401	n	_
33-42	5402-5403	=	_
33-43	5404-5406	39	_
33-44	5407-5408	,	_
33-45	5409-5411	37	_
33-46	5412-5413	,	_
33-47	5414-5417	and	_
33-48	5418-5420	13	_
33-49	5421-5422	,	_
33-50	5423-5435	respectively	_
33-51	5436-5437	)	_
33-52	5438-5441	for	_
33-53	5442-5445	use	_
33-54	5446-5448	in	_
33-55	5449-5452	the	_
33-56	5453-5461	analyses	_
33-57	5462-5463	.	_

34-1	5464-5471	Tobacco	_
34-2	5472-5475	use	_
34-3	5476-5478	We	_
34-4	5479-5483	also	_
34-5	5484-5492	assessed	_
34-6	5493-5498	daily	_
34-7	5499-5506	tobacco	_
34-8	5507-5510	use	_
34-9	5511-5516	given	_
34-10	5517-5524	because	_
34-11	5525-5527	it	_
34-12	5528-5530	is	_
34-13	5531-5541	associated	_
34-14	5542-5546	with	_
34-15	5547-5556	decreased	_
34-16	5557-5571	reward-related	_
34-17	5572-5577	brain	_
34-18	5578-5586	function	_
34-19	5587-5588	.	_

35-1	5589-5591	We	_
35-2	5592-5596	used	_
35-3	5597-5600	the	_
35-4	5601-5608	8-point	_
35-5	5609-5621	Likert-scale	_
35-6	5622-5629	tobacco	_
35-7	5630-5633	use	http://maven.renci.org/NeuroBridge/neurobridge#SternbergItemRecognitionParadigmTask
35-8	5634-5638	item	http://maven.renci.org/NeuroBridge/neurobridge#SternbergItemRecognitionParadigmTask
35-9	5639-5643	from	_
35-10	5644-5647	the	_
35-11	5648-5651	age	_
35-12	5652-5654	22	_
35-13	5655-5669	administration	_
35-14	5670-5672	of	_
35-15	5673-5676	the	_
35-16	5677-5684	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
35-17	5685-5688	and	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
35-18	5689-5693	Drug	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
35-19	5694-5705	Consumption	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
35-20	5706-5719	Questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
35-21	5720-5721	,	_
35-22	5722-5735	dichotomizing	_
35-23	5736-5739	the	_
35-24	5740-5744	item	_
35-25	5745-5749	into	_
35-26	5750-5752	no	_
35-27	5753-5758	daily	_
35-28	5759-5762	use	_
35-29	5763-5764	(	_
35-30	5765-5771	scores	_
35-31	5772-5773	=	_
35-32	5774-5777	0–7	_
35-33	5778-5779	)	_
35-34	5780-5783	and	_
35-35	5784-5789	daily	_
35-36	5790-5793	use	_
35-37	5794-5795	(	_
35-38	5796-5803	score=8	_
35-39	5804-5805	)	_
35-40	5806-5807	.	_

36-1	5808-5818	Depressive	_
36-2	5819-5827	symptoms	_
36-3	5828-5830	We	_
36-4	5831-5835	used	_
36-5	5836-5839	the	_
36-6	5840-5844	Beck	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
36-7	5845-5855	Depression	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
36-8	5856-5865	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
36-9	5866-5867	(	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
36-10	5868-5871	BDI	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
36-11	5872-5873	)	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
36-12	5874-5876	to	_
36-13	5877-5883	assess	_
36-14	5884-5894	depressive	_
36-15	5895-5909	symptomatology	_
36-16	5910-5912	at	_
36-17	5913-5916	age	_
36-18	5917-5919	20	_
36-19	5920-5923	and	_
36-20	5924-5926	22	_
36-21	5927-5928	,	_
36-22	5929-5934	given	_
36-23	5935-5940	prior	_
36-24	5941-5948	reports	_
36-25	5949-5953	that	_
36-26	5954-5964	depression	_
36-27	5965-5967	is	_
36-28	5968-5978	associated	_
36-29	5979-5983	with	_
36-30	5984-5988	both	_
36-31	5989-6000	eveningness	_
36-32	6001-6004	and	_
36-33	6005-6012	altered	_
36-34	6013-6027	reward-related	_
36-35	6028-6033	brain	_
36-36	6034-6042	function	_
36-37	6043-6044	.	_

37-1	6045-6060	Psychopathology	_
37-2	6061-6068	Finally	_
37-3	6069-6070	,	_
37-4	6071-6073	at	_
37-5	6074-6077	age	_
37-6	6078-6080	22	_
37-7	6081-6082	,	_
37-8	6083-6085	we	_
37-9	6086-6094	assessed	_
37-10	6095-6102	current	_
37-11	6103-6106	and	_
37-12	6107-6111	past	_
37-13	6112-6116	Axis	_
37-14	6117-6118	I	_
37-15	6119-6127	clinical	_
37-16	6128-6137	disorders	_
37-17	6138-6143	using	_
37-18	6144-6147	the	_
37-19	6148-6152	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
37-20	6153-6157	with	_
37-21	6158-6159	a	_
37-22	6160-6170	clinically	_
37-23	6171-6178	trained	_
37-24	6179-6184	staff	_
37-25	6185-6191	person	_
37-26	6192-6199	trained	_
37-27	6200-6202	to	_
37-28	6203-6214	reliability	_
37-29	6215-6219	with	_
37-30	6220-6221	a	_
37-31	6222-6230	licensed	_
37-32	6231-6239	clinical	_
37-33	6240-6252	psychologist	_
37-34	6253-6254	.	_

38-1	6255-6258	For	_
38-2	6259-6270	descriptive	_
38-3	6271-6279	purposes	_
38-4	6280-6281	,	_
38-5	6282-6284	we	_
38-6	6285-6292	provide	_
38-7	6293-6304	information	_
38-8	6305-6307	on	_
38-9	6308-6313	Major	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
38-10	6314-6324	Depressive	_
38-11	6325-6333	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#MovementDisorder
38-12	6334-6335	,	_
38-13	6336-6345	Dysthymia	_
38-14	6346-6347	,	_
38-15	6348-6355	Bipolar	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
38-16	6356-6364	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
38-17	6365-6366	,	_
38-18	6367-6374	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
38-19	6375-6385	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
38-20	6386-6387	,	_
38-21	6388-6397	Substance	_
38-22	6398-6408	Dependence	_
38-23	6409-6410	,	_
38-24	6411-6414	and	_
38-25	6415-6425	Antisocial	_
38-26	6426-6437	Personality	_
38-27	6438-6446	Disorder	_
38-28	6447-6452	given	_
38-29	6453-6458	their	_
38-30	6459-6468	relevance	_
38-31	6469-6471	to	_
38-32	6472-6478	reward	_
38-33	6479-6487	function	_
38-34	6488-6489	.	_

39-1	6490-6492	At	_
39-2	6493-6496	age	_
39-3	6497-6499	22	_
39-4	6500-6501	,	_
39-5	6502-6504	11	_
39-6	6505-6506	%	_
39-7	6507-6510	had	_
39-8	6511-6512	a	_
39-9	6513-6520	history	_
39-10	6521-6523	of	_
39-11	6524-6529	Major	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
39-12	6530-6540	Depressive	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
39-13	6541-6549	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
39-14	6550-6551	,	_
39-15	6552-6553	1	_
39-16	6554-6555	%	_
39-17	6556-6559	had	_
39-18	6560-6561	a	_
39-19	6562-6569	history	_
39-20	6570-6572	of	_
39-21	6573-6580	Bipolar	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
39-22	6581-6589	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
39-23	6590-6591	,	_
39-24	6592-6593	5	_
39-25	6594-6595	%	_
39-26	6596-6599	had	_
39-27	6600-6601	a	_
39-28	6602-6609	history	_
39-29	6610-6612	of	_
39-30	6613-6621	Dysthmia	_
39-31	6622-6623	,	_
39-32	6624-6625	2	_
39-33	6626-6627	%	_
39-34	6628-6631	had	_
39-35	6632-6633	a	_
39-36	6634-6641	history	_
39-37	6642-6644	of	_
39-38	6645-6652	Alcohol	_
39-39	6653-6663	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
39-40	6664-6665	,	_
39-41	6666-6667	2	_
39-42	6668-6669	%	_
39-43	6670-6673	had	_
39-44	6674-6675	a	_
39-45	6676-6683	history	_
39-46	6684-6686	of	_
39-47	6687-6698	non-alcohol	_
39-48	6699-6708	Substance	_
39-49	6709-6719	Dependence	_
39-50	6720-6721	,	_
39-51	6722-6725	and	_
39-52	6726-6727	7	_
39-53	6728-6729	%	_
39-54	6730-6733	had	_
39-55	6734-6735	a	_
39-56	6736-6743	history	_
39-57	6744-6746	of	_
39-58	6747-6757	Antisocial	_
39-59	6758-6769	Personality	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityDisorder
39-60	6770-6778	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityDisorder
39-61	6779-6780	.	_

40-1	6781-6784	2.3	_
40-2	6785-6791	Reward	_
40-3	6792-6802	processing	_
40-4	6803-6807	task	_
40-5	6808-6810	We	_
40-6	6811-6819	employed	_
40-7	6820-6821	a	_
40-8	6822-6826	slow	_
40-9	6827-6840	event-related	_
40-10	6841-6845	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
40-11	6846-6859	card-guessing	_
40-12	6860-6868	paradigm	_
40-13	6869-6877	designed	_
40-14	6878-6880	to	_
40-15	6881-6888	examine	_
40-16	6889-6895	neural	_
40-17	6896-6906	reactivity	_
40-18	6907-6909	to	_
40-19	6910-6922	anticipation	_
40-20	6923-6926	and	_
40-21	6927-6934	receipt	_
40-22	6935-6937	of	_
40-23	6938-6946	monetary	_
40-24	6947-6953	reward	_
40-25	6954-6957	and	_
40-26	6958-6962	loss	_
40-27	6963-6966	see	_
40-28	6967-6968	)	_
40-29	6969-6970	.	_

41-1	6971-6977	Trials	_
41-2	6978-6982	were	_
41-3	6983-6992	presented	_
41-4	6993-6995	in	_
41-5	6996-6997	a	_
41-6	6998-7010	pseudorandom	_
41-7	7011-7016	order	_
41-8	7017-7021	with	_
41-9	7022-7035	predetermined	_
41-10	7036-7044	outcomes	_
41-11	7045-7046	.	_

42-1	7047-7051	Each	_
42-2	7052-7056	20-s	_
42-3	7057-7062	trial	_
42-4	7063-7072	consisted	_
42-5	7073-7075	of	_
42-6	7076-7077	a	_
42-7	7078-7081	4-s	_
42-8	7082-7090	decision	_
42-9	7091-7096	phase	_
42-10	7097-7101	when	_
42-11	7102-7114	participants	_
42-12	7115-7122	guessed	_
42-13	7123-7130	whether	_
42-14	7131-7134	the	_
42-15	7135-7140	value	_
42-16	7141-7143	of	_
42-17	7144-7145	a	_
42-18	7146-7154	visually	_
42-19	7155-7164	presented	_
42-20	7165-7169	card	_
42-21	7170-7174	with	_
42-22	7175-7176	a	_
42-23	7177-7185	possible	_
42-24	7186-7191	value	_
42-25	7192-7194	of	_
42-26	7195-7198	1–9	_
42-27	7199-7202	was	_
42-28	7203-7209	higher	_
42-29	7210-7212	or	_
42-30	7213-7218	lower	_
42-31	7219-7223	than	_
42-32	7224-7225	5	_
42-33	7226-7227	,	_
42-34	7228-7229	a	_
42-35	7230-7233	6-s	_
42-36	7234-7246	anticipation	_
42-37	7247-7253	period	_
42-38	7254-7258	when	_
42-39	7259-7262	the	_
42-40	7263-7268	trial	_
42-41	7269-7273	type	_
42-42	7274-7275	(	_
42-43	7276-7291	possible-reward	_
42-44	7292-7294	or	_
42-45	7295-7308	possible-loss	_
42-46	7309-7310	)	_
42-47	7311-7314	was	_
42-48	7315-7324	displayed	_
42-49	7325-7326	,	_
42-50	7327-7328	a	_
42-51	7329-7332	1–s	_
42-52	7333-7340	outcome	_
42-53	7341-7347	period	_
42-54	7348-7351	the	_
42-55	7352-7361	numerical	_
42-56	7362-7367	value	_
42-57	7368-7370	of	_
42-58	7371-7374	the	_
42-59	7375-7379	card	_
42-60	7380-7383	and	_
42-61	7384-7388	then	_
42-62	7389-7396	outcome	_
42-63	7397-7405	feedback	_
42-64	7406-7407	(	_
42-65	7408-7411	win	_
42-66	7412-7413	,	_
42-67	7414-7418	loss	_
42-68	7419-7420	,	_
42-69	7421-7423	or	_
42-70	7424-7433	no-change	_
42-71	7434-7435	)	_
42-72	7436-7440	were	_
42-73	7441-7450	presented	_
42-74	7451-7452	,	_
42-75	7453-7456	and	_
42-76	7457-7458	a	_
42-77	7459-7462	9-s	_
42-78	7463-7476	interstimulus	_
42-79	7477-7485	interval	_
42-80	7486-7487	.	_

43-1	7488-7490	In	_
43-2	7491-7497	reward	_
43-3	7498-7504	trials	_
43-4	7505-7517	participants	_
43-5	7518-7523	would	_
43-6	7524-7527	win	_
43-7	7528-7529	$	_
43-8	7530-7531	1	_
43-9	7532-7534	if	_
43-10	7535-7540	their	_
43-11	7541-7546	guess	_
43-12	7547-7550	was	_
43-13	7551-7558	correct	_
43-14	7559-7562	and	_
43-15	7563-7568	there	_
43-16	7569-7574	would	_
43-17	7575-7577	be	_
43-18	7578-7587	no-change	_
43-19	7588-7590	in	_
43-20	7591-7599	earnings	_
43-21	7600-7602	if	_
43-22	7603-7608	their	_
43-23	7609-7614	guess	_
43-24	7615-7618	was	_
43-25	7619-7628	incorrect	_
43-26	7629-7630	.	_

44-1	7631-7633	In	_
44-2	7634-7638	loss	_
44-3	7639-7645	trials	_
44-4	7646-7658	participants	_
44-5	7659-7664	would	_
44-6	7665-7669	lose	_
44-7	7670-7672	50	_
44-8	7673-7678	cents	_
44-9	7679-7681	if	_
44-10	7682-7687	their	_
44-11	7688-7693	guess	_
44-12	7694-7697	was	_
44-13	7698-7707	incorrect	_
44-14	7708-7711	and	_
44-15	7712-7717	there	_
44-16	7718-7723	would	_
44-17	7724-7726	be	_
44-18	7727-7736	no-change	_
44-19	7737-7739	in	_
44-20	7740-7748	earnings	_
44-21	7749-7751	if	_
44-22	7752-7757	their	_
44-23	7758-7763	guess	_
44-24	7764-7767	was	_
44-25	7768-7775	correct	_
44-26	7776-7777	.	_

45-1	7778-7789	Twenty-four	_
45-2	7790-7796	trials	_
45-3	7797-7801	were	_
45-4	7802-7811	presented	_
45-5	7812-7814	in	http://maven.renci.org/NeuroBridge/neurobridge#OneLeadElectrocardiograph
45-6	7815-7818	one	http://maven.renci.org/NeuroBridge/neurobridge#OneLeadElectrocardiograph
45-7	7819-7822	run	http://maven.renci.org/NeuroBridge/neurobridge#OneLeadElectrocardiograph
45-8	7823-7827	with	http://maven.renci.org/NeuroBridge/neurobridge#OneLeadElectrocardiograph
45-9	7828-7830	12	_
45-10	7831-7850	reward-anticipation	_
45-11	7851-7854	and	_
45-12	7855-7857	12	_
45-13	7858-7875	loss-anticipation	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
45-14	7876-7882	trials	http://maven.renci.org/NeuroBridge/neurobridge#Unmedicated
45-15	7883-7884	.	_

46-1	7885-7891	Within	_
46-2	7892-7911	reward-anticipation	_
46-3	7912-7918	trials	_
46-4	7919-7924	there	_
46-5	7925-7929	were	_
46-6	7930-7931	a	_
46-7	7932-7940	balanced	_
46-8	7941-7947	number	_
46-9	7948-7950	of	_
46-10	7951-7962	win-outcome	_
46-11	7963-7966	and	_
46-12	7967-7976	no-change	_
46-13	7977-7984	outcome	_
46-14	7985-7991	trials	_
46-15	7992-7993	.	_

47-1	7994-7996	In	_
47-2	7997-8000	the	_
47-3	8001-8008	present	_
47-4	8009-8014	study	_
47-5	8015-8017	we	_
47-6	8018-8023	focus	_
47-7	8024-8026	on	_
47-8	8027-8030	the	_
47-9	8031-8043	anticipation	_
47-10	8044-8047	and	_
47-11	8048-8055	outcome	_
47-12	8056-8062	phases	_
47-13	8063-8065	of	_
47-14	8066-8069	the	_
47-15	8070-8076	reward	_
47-16	8077-8083	trials	_
47-17	8084-8085	,	_
47-18	8086-8091	based	_
47-19	8092-8094	on	_
47-20	8095-8103	evidence	_
47-21	8104-8108	that	_
47-22	8109-8118	circadian	_
47-23	8119-8129	preference	_
47-24	8130-8132	is	_
47-25	8133-8137	more	_
47-26	8138-8146	strongly	_
47-27	8147-8154	related	_
47-28	8155-8157	to	_
47-29	8158-8164	reward	_
47-30	8165-8166	,	_
47-31	8167-8177	appetitive	_
47-32	8178-8188	motivation	_
47-33	8189-8190	,	_
47-34	8191-8194	and	_
47-35	8195-8203	positive	_
47-36	8204-8210	affect	_
47-37	8211-8215	than	_
47-38	8216-8218	to	_
47-39	8219-8227	negative	_
47-40	8228-8234	affect	_
47-41	8235-8244	processes	_
47-42	8245-8246	,	_
47-43	8247-8250	and	_
47-44	8251-8263	specifically	_
47-45	8264-8268	used	_
47-46	8269-8272	the	_
47-47	8273-8279	reward	_
47-48	8280-8292	anticipation	_
47-49	8293-8294	>	_
47-50	8295-8303	baseline	_
47-51	8304-8307	and	_
47-52	8308-8314	reward	_
47-53	8315-8318	win	_
47-54	8319-8320	>	_
47-55	8321-8329	baseline	_
47-56	8330-8339	contrasts	_
47-57	8340-8341	,	_
47-58	8342-8344	in	_
47-59	8345-8350	which	_
47-60	8351-8359	baseline	_
47-61	8360-8363	was	_
47-62	8364-8371	defined	_
47-63	8372-8374	as	_
47-64	8375-8378	the	_
47-65	8379-8383	last	_
47-66	8384-8385	3	_
47-67	8386-8387	s	_
47-68	8388-8390	of	_
47-69	8391-8394	the	_
47-70	8395-8408	interstimulus	_
47-71	8409-8417	interval	_
47-72	8418-8419	.	_

48-1	8420-8427	Outcome	_
48-2	8428-8441	probabilities	_
48-3	8442-8446	were	_
48-4	8447-8452	fixed	_
48-5	8453-8463	trial-wise	_
48-6	8464-8466	to	_
48-7	8467-8473	ensure	_
48-8	8474-8476	an	_
48-9	8477-8486	identical	_
48-10	8487-8495	win/loss	_
48-11	8496-8500	time	_
48-12	8501-8507	series	_
48-13	8508-8516	modeling	_
48-14	8517-8520	and	_
48-15	8521-8528	pattern	_
48-16	8529-8531	of	_
48-17	8532-8539	outcome	_
48-18	8540-8551	experiences	_
48-19	8552-8555	for	_
48-20	8556-8561	every	_
48-21	8562-8573	participant	_
48-22	8574-8575	.	_

49-1	8576-8580	Each	_
49-2	8581-8592	participant	_
49-3	8593-8596	was	_
49-4	8597-8602	given	_
49-5	8603-8604	$	_
49-6	8605-8607	10	_
49-7	8608-8610	in	_
49-8	8611-8619	earnings	_
49-9	8620-8621	.	_

50-1	8622-8634	Participants	_
50-2	8635-8639	were	_
50-3	8640-8647	unaware	_
50-4	8648-8650	of	_
50-5	8651-8654	the	_
50-6	8655-8660	fixed	_
50-7	8661-8668	outcome	_
50-8	8669-8682	probabilities	_
50-9	8683-8685	in	_
50-10	8686-8689	the	_
50-11	8690-8698	paradigm	_
50-12	8699-8700	,	_
50-13	8701-8704	and	_
50-14	8705-8709	were	_
50-15	8710-8713	led	_
50-16	8714-8716	to	_
50-17	8717-8724	believe	_
50-18	8725-8730	their	_
50-19	8731-8742	performance	_
50-20	8743-8748	would	_
50-21	8749-8758	determine	_
50-22	8759-8762	net	_
50-23	8763-8771	monetary	_
50-24	8772-8776	gain	_
50-25	8777-8778	.	_

51-1	8779-8791	Neuroimaging	_
51-2	8792-8796	data	_
51-3	8797-8801	were	_
51-4	8802-8811	collected	_
51-5	8812-8817	using	_
51-6	8818-8819	a	_
51-7	8820-8823	3.0	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
51-8	8824-8825	T	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
51-9	8826-8833	Siemens	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
51-10	8834-8838	Trio	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
51-11	8839-8842	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
51-12	8843-8850	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
51-13	8851-8853	at	_
51-14	8854-8857	the	_
51-15	8858-8868	University	_
51-16	8869-8871	of	_
51-17	8872-8882	Pittsburgh	_
51-18	8883-8884	.	_

52-1	8885-8895	Structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
52-2	8896-8898	3D	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
52-3	8899-8904	axial	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
52-4	8905-8911	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
52-5	8912-8918	images	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
52-6	8919-8923	were	_
52-7	8924-8932	acquired	_
52-8	8933-8935	in	_
52-9	8936-8939	the	_
52-10	8940-8944	same	_
52-11	8945-8952	session	_
52-12	8953-8954	(	_
52-13	8955-8962	TE=3.29	_
52-14	8963-8965	ms	_
52-15	8966-8967	;	_
52-16	8968-8975	TR=2200	_
52-17	8976-8978	ms	_
52-18	8979-8980	;	_
52-19	8981-8985	Flip	_
52-20	8986-8994	Angle=9°	_
52-21	8995-8996	;	_
52-22	8997-9002	Field	_
52-23	9003-9005	of	_
52-24	9006-9014	View=256	_
52-25	9015-9016	×	_
52-26	9017-9020	192	_
52-27	9021-9024	mm2	_
52-28	9025-9026	;	_
52-29	9027-9044	Slice-Thickness=1	_
52-30	9045-9047	mm	_
52-31	9048-9049	;	_
52-32	9050-9056	Matrix	_
52-33	9057-9058	:	_
52-34	9059-9062	256	_
52-35	9063-9064	×	_
52-36	9065-9068	256	_
52-37	9069-9070	;	_
52-38	9071-9074	192	_
52-39	9075-9085	continuous	_
52-40	9086-9092	slices	_
52-41	9093-9094	)	_
52-42	9095-9096	.	_

53-1	9097-9101	Mean	_
53-2	9102-9135	blood-oxygenation-level-dependent	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
53-3	9136-9137	(	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
53-4	9138-9142	BOLD	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
53-5	9143-9144	)	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
53-6	9145-9151	images	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
53-7	9152-9156	were	_
53-8	9157-9161	then	_
53-9	9162-9170	acquired	_
53-10	9171-9175	with	_
53-11	9176-9177	a	_
53-12	9178-9186	gradient	_
53-13	9187-9191	echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
53-14	9192-9195	EPI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
53-15	9196-9204	sequence	_
53-16	9205-9211	during	_
53-17	9212-9218	13-min	_
53-18	9219-9227	covering	_
53-19	9228-9230	39	_
53-20	9231-9236	axial	_
53-21	9237-9243	slices	_
53-22	9244-9245	(	_
53-23	9246-9249	3.1	_
53-24	9250-9252	mm	_
53-25	9253-9258	thick	_
53-26	9259-9260	;	_
53-27	9261-9274	TR/TE=2000/28	_
53-28	9275-9277	ms	_
53-29	9278-9279	;	_
53-30	9280-9291	FOV=205×205	_
53-31	9292-9294	mm	_
53-32	9295-9296	;	_
53-33	9297-9303	matrix	_
53-34	9304-9306	64	_
53-35	9307-9308	×	_
53-36	9309-9311	64	_
53-37	9312-9313	;	_
53-38	9314-9318	Flip	_
53-39	9319-9324	Angle	_
53-40	9325-9328	90°	_
53-41	9329-9330	)	_
53-42	9331-9332	.	_

54-1	9333-9336	2.4	_
54-2	9337-9341	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
54-3	9342-9355	preprocessing	_
54-4	9356-9359	and	_
54-5	9360-9367	initial	_
54-6	9368-9376	analyses	_
54-7	9377-9389	Neuroimaging	_
54-8	9390-9394	data	_
54-9	9395-9399	were	_
54-10	9400-9412	preprocessed	_
54-11	9413-9416	and	_
54-12	9417-9425	analyzed	_
54-13	9426-9430	with	_
54-14	9431-9442	Statistical	_
54-15	9443-9453	Parametric	_
54-16	9454-9461	Mapping	_
54-17	9462-9470	software	_
54-18	9471-9472	,	_
54-19	9473-9482	Version-8	_
54-20	9483-9484	(	_
54-21	9485-9489	SPM8	_
54-22	9490-9491	;	_
54-23	9492-9496	http	_
54-24	9497-9498	:	_
54-25	9499-9526	//www.fil.ion.ucl.ac.uk/spm	_
54-26	9527-9528	)	_
54-27	9529-9530	.	_

55-1	9531-9535	Data	_
55-2	9536-9539	for	_
55-3	9540-9544	each	_
55-4	9545-9556	participant	_
55-5	9557-9561	were	_
55-6	9562-9571	realigned	_
55-7	9572-9574	to	_
55-8	9575-9578	the	_
55-9	9579-9584	first	_
55-10	9585-9591	volume	_
55-11	9592-9594	in	_
55-12	9595-9598	the	_
55-13	9599-9603	time	_
55-14	9604-9610	series	_
55-15	9611-9613	to	_
55-16	9614-9621	correct	_
55-17	9622-9625	for	_
55-18	9626-9630	head	_
55-19	9631-9637	motion	_
55-20	9638-9639	.	_

56-1	9640-9644	Data	_
56-2	9645-9649	sets	_
56-3	9650-9654	were	_
56-4	9655-9659	then	_
56-5	9660-9668	selected	_
56-6	9669-9672	for	_
56-7	9673-9680	quality	_
56-8	9681-9686	based	_
56-9	9687-9689	on	_
56-10	9690-9693	our	_
56-11	9694-9702	standard	_
56-12	9703-9715	small-motion	_
56-13	9716-9726	correction	_
56-14	9727-9728	(	_
56-15	9729-9730	<	_
56-16	9731-9732	2	_
56-17	9733-9735	mm	_
56-18	9736-9738	on	_
56-19	9739-9746	average	_
56-20	9747-9753	across	_
56-21	9754-9757	all	_
56-22	9758-9764	frames	_
56-23	9765-9766	)	_
56-24	9767-9770	and	_
56-25	9771-9779	adequate	_
56-26	9780-9788	coverage	_
56-27	9789-9791	of	_
56-28	9792-9795	the	_
56-29	9796-9803	ventral	_
56-30	9804-9812	striatum	_
56-31	9813-9814	(	_
56-32	9815-9816	>	_
56-33	9817-9819	80	_
56-34	9820-9821	%	_
56-35	9822-9823	)	_
56-36	9824-9825	.	_

57-1	9826-9835	Realigned	_
57-2	9836-9842	images	_
57-3	9843-9847	were	_
57-4	9848-9852	then	_
57-5	9853-9865	coregistered	_
57-6	9866-9870	with	_
57-7	9871-9874	the	_
57-8	9875-9882	subject	_
57-9	9883-9884	’	_
57-10	9885-9886	s	_
57-11	9887-9897	anatomical	_
57-12	9898-9903	image	_
57-13	9904-9905	,	_
57-14	9906-9915	segmented	_
57-15	9916-9918	to	_
57-16	9919-9927	restrict	_
57-17	9928-9936	analyses	_
57-18	9937-9939	to	_
57-19	9940-9944	gray	_
57-20	9945-9951	matter	_
57-21	9952-9953	,	_
57-22	9954-9964	normalized	_
57-23	9965-9967	to	_
57-24	9968-9976	standard	_
57-25	9977-9985	Montreal	_
57-26	9986-9998	Neurological	_
57-27	9999-10008	Institute	_
57-28	10009-10010	(	_
57-29	10011-10014	MNI	_
57-30	10015-10016	)	_
57-31	10017-10025	template	_
57-32	10026-10027	,	_
57-33	10028-10031	and	_
57-34	10032-10041	spatially	_
57-35	10042-10050	smoothed	_
57-36	10051-10055	with	_
57-37	10056-10057	a	_
57-38	10058-10066	Gaussian	_
57-39	10067-10073	kernel	_
57-40	10074-10076	of	_
57-41	10077-10078	6	_
57-42	10079-10081	mm	_
57-43	10082-10092	full-width	_
57-44	10093-10095	at	_
57-45	10096-10108	half-maximum	_
57-46	10109-10110	.	_

58-1	10111-10112	A	_
58-2	10113-10124	first-level	_
58-3	10125-10137	fixed-effect	_
58-4	10138-10143	model	_
58-5	10144-10147	was	_
58-6	10148-10159	constructed	_
58-7	10160-10163	for	_
58-8	10164-10168	each	_
58-9	10169-10180	participant	_
58-10	10181-10184	and	_
58-11	10185-10189	scan	_
58-12	10190-10193	and	_
58-13	10194-10207	predetermined	_
58-14	10208-10217	condition	_
58-15	10218-10225	effects	_
58-16	10226-10228	at	_
58-17	10229-10233	each	_
58-18	10234-10239	voxel	_
58-19	10240-10244	were	_
58-20	10245-10255	calculated	_
58-21	10256-10261	using	_
58-22	10262-10263	a	_
58-23	10264-10275	t-statistic	_
58-24	10276-10277	,	_
58-25	10278-10287	producing	_
58-26	10288-10289	a	_
58-27	10290-10301	statistical	_
58-28	10302-10307	image	_
58-29	10308-10311	for	_
58-30	10312-10315	the	_
58-31	10316-10336	reward-anticipation-	_
58-32	10337-10351	minus-baseline	_
58-33	10352-10355	and	_
58-34	10356-10408	win-outcome-after-reward-anticipation-minus-baseline	_
58-35	10409-10417	contrast	_
58-36	10418-10419	.	_

59-1	10420-10431	First-level	_
59-2	10432-10440	contrast	_
59-3	10441-10447	images	_
59-4	10448-10452	were	_
59-5	10453-10457	then	_
59-6	10458-10466	included	_
59-7	10467-10469	in	_
59-8	10470-10482	second-level	_
59-9	10483-10494	whole-brain	_
59-10	10495-10498	and	_
59-11	10499-10505	region	_
59-12	10506-10508	of	_
59-13	10509-10517	interest	_
59-14	10518-10519	(	_
59-15	10520-10523	ROI	_
59-16	10524-10525	)	_
59-17	10526-10534	analyses	_
59-18	10535-10536	.	_

60-1	10537-10540	The	_
60-2	10541-10543	VS	_
60-3	10544-10547	ROI	_
60-4	10548-10551	was	_
60-5	10552-10563	constructed	_
60-6	10564-10569	using	_
60-7	10570-10573	the	_
60-8	10574-10577	WFU	_
60-9	10578-10587	Pickatlas	_
60-10	10588-10592	Tool	_
60-11	10593-10594	(	_
60-12	10595-10600	v1.04	_
60-13	10601-10602	)	_
60-14	10603-10606	and	_
60-15	10607-10614	defined	_
60-16	10615-10617	as	_
60-17	10618-10619	a	_
60-18	10620-10626	sphere	_
60-19	10627-10631	20mm	_
60-20	10632-10634	in	_
60-21	10635-10641	radius	_
60-22	10642-10643	,	_
60-23	10644-10652	centered	_
60-24	10653-10655	on	_
60-25	10656-10659	the	_
60-26	10660-10667	ventral	_
60-27	10668-10676	striatum	_
60-28	10677-10682	using	_
60-29	10683-10692	Talairach	_
60-30	10693-10704	coordinates	_
60-31	10705-10708	x=0	_
60-32	10709-10710	,	_
60-33	10711-10715	y=10	_
60-34	10716-10717	,	_
60-35	10718-10721	and	_
60-36	10722-10727	z=−10	_
60-37	10728-10729	,	_
60-38	10730-10733	and	_
60-39	10734-10746	encompassing	_
60-40	10747-10750	the	_
60-41	10751-10755	head	_
60-42	10756-10758	of	_
60-43	10759-10762	the	_
60-44	10763-10770	caudate	_
60-45	10771-10778	nucleus	_
60-46	10779-10782	and	_
60-47	10783-10790	ventral	_
60-48	10791-10796	areas	_
60-49	10797-10798	.	_

61-1	10799-10802	The	_
61-2	10803-10807	mPFC	_
61-3	10808-10811	ROI	_
61-4	10812-10815	was	_
61-5	10816-10827	constructed	_
61-6	10828-10833	using	_
61-7	10834-10837	the	_
61-8	10838-10847	PickAtlas	_
61-9	10848-10851	and	_
61-10	10852-10859	defined	_
61-11	10860-10862	as	_
61-12	10863-10864	a	_
61-13	10865-10875	5393-voxel	_
61-14	10876-10882	sphere	_
61-15	10883-10892	including	_
61-16	10893-10899	medial	_
61-17	10900-10908	Brodmann	_
61-18	10909-10913	Area	_
61-19	10914-10915	(	_
61-20	10916-10918	BA	_
61-21	10919-10920	)	_
61-22	10921-10923	10	_
61-23	10924-10927	and	_
61-24	10928-10932	BA32	_
61-25	10933-10934	,	_
61-26	10935-10938	key	_
61-27	10939-10949	projection	_
61-28	10950-10957	targets	_
61-29	10958-10960	of	_
61-30	10961-10969	midbrain	_
61-31	10970-10978	dopamine	_
61-32	10979-10986	neurons	_
61-33	10987-10988	,	_
61-34	10989-10994	which	_
61-35	10995-11006	demonstrate	_
61-36	11007-11019	connectivity	_
61-37	11020-11024	with	_
61-38	11025-11028	the	_
61-39	11029-11036	ventral	_
61-40	11037-11045	striatum	_
61-41	11046-11047	,	_
61-42	11048-11051	and	_
61-43	11052-11057	which	_
61-44	11058-11062	have	_
61-45	11063-11067	been	_
61-46	11068-11078	implicated	_
61-47	11079-11081	in	_
61-48	11082-11092	evaluating	_
61-49	11093-11096	the	_
61-50	11097-11105	relative	_
61-51	11106-11111	value	_
61-52	11112-11114	of	_
61-53	11115-11122	rewards	_
61-54	11123-11126	and	_
61-55	11127-11142	reward-directed	_
61-56	11143-11151	behavior	_
61-57	11152-11153	.	_

62-1	11154-11156	At	_
62-2	11157-11160	the	_
62-3	11161-11167	second	_
62-4	11168-11173	level	_
62-5	11174-11175	,	_
62-6	11176-11178	we	_
62-7	11179-11183	used	_
62-8	11184-11192	1-sample	_
62-9	11193-11200	t-tests	_
62-10	11201-11203	in	_
62-11	11204-11207	the	_
62-12	11208-11211	age	_
62-13	11212-11214	20	_
62-14	11215-11221	sample	_
62-15	11222-11224	to	_
62-16	11225-11234	ascertain	_
62-17	11235-11238	the	_
62-18	11239-11243	main	_
62-19	11244-11250	effect	_
62-20	11251-11253	of	_
62-21	11254-11258	task	_
62-22	11259-11260	(	_
62-23	11261-11282	anticipation-baseline	_
62-24	11283-11286	and	_
62-25	11287-11299	win-baseline	_
62-26	11300-11309	contrasts	_
62-27	11310-11311	)	_
62-28	11312-11314	in	_
62-29	11315-11319	each	_
62-30	11320-11323	ROI	_
62-31	11324-11325	,	_
62-32	11326-11331	using	_
62-33	11332-11333	a	_
62-34	11334-11340	height	_
62-35	11341-11350	threshold	_
62-36	11351-11353	of	_
62-37	11354-11355	p	_
62-38	11356-11357	<	_
62-39	11358-11363	0.001	_
62-40	11364-11367	and	_
62-41	11368-11369	a	_
62-42	11370-11383	cluster-level	_
62-43	11384-11393	threshold	_
62-44	11394-11396	of	_
62-45	11397-11401	pFWE	_
62-46	11402-11403	<	_
62-47	11404-11408	0.05	_
62-48	11409-11410	.	_

63-1	11411-11412	A	_
63-2	11413-11419	single	_
63-3	11420-11427	cluster	_
63-4	11428-11431	was	_
63-5	11432-11442	identified	_
63-6	11443-11445	in	_
63-7	11446-11450	each	_
63-8	11451-11453	of	_
63-9	11454-11457	the	_
63-10	11458-11460	VS	_
63-11	11461-11464	and	_
63-12	11465-11469	mPFC	_
63-13	11470-11474	ROIs	_
63-14	11475-11476	.	_

64-1	11477-11479	To	_
64-2	11480-11485	focus	_
64-3	11486-11488	on	_
64-4	11489-11495	voxels	_
64-5	11496-11502	within	_
64-6	11503-11507	each	_
64-7	11508-11511	ROI	_
64-8	11512-11522	responsive	_
64-9	11523-11525	to	_
64-10	11526-11529	the	_
64-11	11530-11536	reward	_
64-12	11537-11541	task	_
64-13	11542-11543	,	_
64-14	11544-11546	we	_
64-15	11547-11554	created	_
64-16	11555-11565	functional	_
64-17	11566-11571	masks	_
64-18	11572-11577	based	_
64-19	11578-11580	on	_
64-20	11581-11586	these	_
64-21	11587-11589	VS	_
64-22	11590-11593	and	_
64-23	11594-11598	mPFC	_
64-24	11599-11607	clusters	_
64-25	11608-11609	(	_
64-26	11610-11613	see	_
64-27	11614-11621	Figures	_
64-28	11622-11624	S1	_
64-29	11625-11628	and	_
64-30	11629-11631	S2	_
64-31	11632-11634	in	_
64-32	11635-11638	the	_
64-33	11639-11649	Supplement	_
64-34	11650-11651	)	_
64-35	11652-11653	,	_
64-36	11654-11657	and	_
64-37	11658-11662	then	_
64-38	11663-11671	employed	_
64-39	11672-11675	the	_
64-40	11676-11683	Marsbar	_
64-41	11684-11691	toolbox	_
64-42	11692-11694	to	_
64-43	11695-11702	extract	_
64-44	11703-11706	the	_
64-45	11707-11711	mean	_
64-46	11712-11722	activation	_
64-47	11723-11729	across	_
64-48	11730-11734	each	_
64-49	11735-11745	functional	_
64-50	11746-11753	cluster	_
64-51	11754-11756	in	_
64-52	11757-11761	both	_
64-53	11762-11765	the	_
64-54	11766-11769	age	_
64-55	11770-11772	20	_
64-56	11773-11776	and	_
64-57	11777-11780	age	_
64-58	11781-11783	22	_
64-59	11784-11792	datasets	_
64-60	11793-11794	.	_

65-1	11795-11800	These	_
65-2	11801-11805	mean	_
65-3	11806-11817	activations	_
65-4	11818-11824	across	_
65-5	11825-11827	VS	_
65-6	11828-11831	and	_
65-7	11832-11836	mPFC	_
65-8	11837-11841	were	_
65-9	11842-11854	subsequently	_
65-10	11855-11859	used	_
65-11	11860-11862	in	_
65-12	11863-11866	all	_
65-13	11867-11876	remaining	_
65-14	11877-11885	analyses	_
65-15	11886-11887	.	_

66-1	11888-11890	We	_
66-2	11891-11899	examined	_
66-3	11900-11903	the	_
66-4	11904-11916	distribution	_
66-5	11917-11919	of	_
66-6	11920-11923	the	_
66-7	11924-11933	extracted	_
66-8	11934-11937	ROI	_
66-9	11938-11942	data	_
66-10	11943-11944	,	_
66-11	11945-11954	excluding	_
66-12	11955-11956	4	_
66-13	11957-11969	participants	_
66-14	11970-11974	with	_
66-15	11975-11981	values	_
66-16	11982-11989	greater	_
66-17	11990-11994	than	_
66-18	11995-11998	3SD	_
66-19	11999-12003	from	_
66-20	12004-12007	the	_
66-21	12008-12012	mean	_
66-22	12013-12014	,	_
66-23	12015-12024	resulting	_
66-24	12025-12027	in	_
66-25	12028-12029	a	_
66-26	12030-12036	sample	_
66-27	12037-12039	of	_
66-28	12040-12042	89	_
66-29	12043-12055	participants	_
66-30	12056-12057	.	_

67-1	12058-12062	Also	_
67-2	12063-12064	,	_
67-3	12065-12070	based	_
67-4	12071-12073	on	_
67-5	12074-12079	prior	_
67-6	12080-12088	evidence	_
67-7	12089-12091	of	_
67-8	12092-12101	circadian	_
67-9	12102-12109	rhythms	_
67-10	12110-12112	in	_
67-11	12113-12119	reward	_
67-12	12120-12129	processes	_
67-13	12130-12131	,	_
67-14	12132-12141	including	_
67-15	12142-12156	reward-related	_
67-16	12157-12162	brain	_
67-17	12163-12173	activation	_
67-18	12174-12175	(	_
67-19	12176-12177	,	_
67-20	12178-12179	)	_
67-21	12180-12181	,	_
67-22	12182-12184	we	_
67-23	12185-12193	explored	_
67-24	12194-12206	correlations	_
67-25	12207-12214	between	_
67-26	12215-12218	the	_
67-27	12219-12228	extracted	_
67-28	12229-12232	ROI	_
67-29	12233-12237	data	_
67-30	12238-12241	and	_
67-31	12242-12245	the	_
67-32	12246-12250	time	_
67-33	12251-12253	of	_
67-34	12254-12258	scan	_
67-35	12259-12260	(	_
67-36	12261-12266	which	_
67-37	12267-12273	ranged	_
67-38	12274-12278	from	_
67-39	12279-12286	9AM–4PM	_
67-40	12287-12288	)	_
67-41	12289-12290	.	_

68-1	12291-12296	There	_
68-2	12297-12301	were	_
68-3	12302-12304	no	_
68-4	12305-12316	significant	_
68-5	12317-12329	correlations	_
68-6	12330-12337	between	_
68-7	12338-12347	extracted	_
68-8	12348-12351	ROI	_
68-9	12352-12356	data	_
68-10	12357-12360	and	_
68-11	12361-12364	the	_
68-12	12365-12369	time	_
68-13	12370-12372	of	_
68-14	12373-12377	scan	_
68-15	12378-12379	,	_
68-16	12380-12383	and	_
68-17	12384-12388	thus	_
68-18	12389-12393	time	_
68-19	12394-12396	of	_
68-20	12397-12401	scan	_
68-21	12402-12405	was	_
68-22	12406-12409	not	_
68-23	12410-12414	used	_
68-24	12415-12417	as	_
68-25	12418-12419	a	_
68-26	12420-12429	covariate	_
68-27	12430-12432	in	_
68-28	12433-12443	subsequent	_
68-29	12444-12452	analyses	_
68-30	12453-12454	.	_

69-1	12455-12458	2.5	_
69-2	12459-12463	Main	_
69-3	12464-12468	data	_
69-4	12469-12477	analyses	_
69-5	12478-12485	Changes	_
69-6	12486-12488	in	_
69-7	12489-12498	circadian	_
69-8	12499-12509	preference	_
69-9	12510-12511	,	_
69-10	12512-12521	substance	_
69-11	12522-12530	outcomes	_
69-12	12531-12532	,	_
69-13	12533-12536	and	_
69-14	12537-12551	reward-related	_
69-15	12552-12557	brain	_
69-16	12558-12566	function	_
69-17	12567-12571	were	_
69-18	12572-12580	examined	_
69-19	12581-12584	via	_
69-20	12585-12598	paired-sample	_
69-21	12599-12606	t-tests	_
69-22	12607-12609	or	_
69-23	12610-12613	the	_
69-24	12614-12622	Wilcoxon	_
69-25	12623-12629	Signed	_
69-26	12630-12635	Ranks	_
69-27	12636-12640	Test	_
69-28	12641-12642	(	_
69-29	12643-12651	cannabis	_
69-30	12652-12655	use	_
69-31	12656-12660	only	_
69-32	12661-12662	)	_
69-33	12663-12664	.	_

70-1	12665-12671	Fisher	_
70-2	12672-12673	’	_
70-3	12674-12675	s	_
70-4	12676-12681	Exact	_
70-5	12682-12686	Test	_
70-6	12687-12688	(	_
70-7	12689-12692	FET	_
70-8	12693-12694	)	_
70-9	12695-12698	was	_
70-10	12699-12703	used	_
70-11	12704-12706	to	_
70-12	12707-12714	examine	_
70-13	12715-12722	changes	_
70-14	12723-12725	in	_
70-15	12726-12738	distribution	_
70-16	12739-12741	of	_
70-17	12742-12751	circadian	_
70-18	12752-12762	preference	_
70-19	12763-12768	types	_
70-20	12769-12770	.	_

71-1	12771-12783	Hypothesized	_
71-2	12784-12796	associations	_
71-3	12797-12804	between	_
71-4	12805-12814	circadian	_
71-5	12815-12825	preference	_
71-6	12826-12827	,	_
71-7	12828-12842	reward-related	_
71-8	12843-12848	brain	_
71-9	12849-12857	function	_
71-10	12858-12859	,	_
71-11	12860-12863	and	_
71-12	12864-12873	substance	_
71-13	12874-12877	use	_
71-14	12878-12882	were	_
71-15	12883-12892	initially	_
71-16	12893-12901	examined	_
71-17	12902-12905	via	_
71-18	12906-12915	bivariate	_
71-19	12916-12923	Pearson	_
71-20	12924-12925	’	_
71-21	12926-12927	s	_
71-22	12928-12940	correlations	_
71-23	12941-12943	in	_
71-24	12944-12948	SPSS	_
71-25	12949-12951	22	_
71-26	12952-12953	(	_
71-27	12954-12957	IBM	_
71-28	12958-12969	Corporation	_
71-29	12970-12971	,	_
71-30	12972-12976	2013	_
71-31	12977-12978	)	_
71-32	12979-12980	.	_

72-1	12981-12992	Significant	_
72-2	12993-13006	relationships	_
72-3	13007-13011	were	_
72-4	13012-13024	subsequently	_
72-5	13025-13034	evaluated	_
72-6	13035-13040	using	_
72-7	13041-13050	cross-lag	_
72-8	13051-13056	panel	_
72-9	13057-13060	and	_
72-10	13061-13070	mediation	_
72-11	13071-13079	analyses	_
72-12	13080-13082	in	_
72-13	13083-13088	Mplus	_
72-14	13089-13090	7	_
72-15	13091-13092	.	_

73-1	13093-13102	Cross-lag	_
73-2	13103-13108	panel	_
73-3	13109-13117	analyses	_
73-4	13118-13122	with	_
73-5	13123-13130	maximum	_
73-6	13131-13141	likelihood	_
73-7	13142-13152	estimation	_
73-8	13153-13159	tested	_
73-9	13160-13167	whether	_
73-10	13168-13177	circadian	_
73-11	13178-13188	preference	_
73-12	13189-13191	at	_
73-13	13192-13195	age	_
73-14	13196-13198	20	_
73-15	13199-13208	predicted	_
73-16	13209-13223	reward-related	_
73-17	13224-13229	brain	_
73-18	13230-13238	function	_
73-19	13239-13241	in	_
73-20	13242-13245	the	_
73-21	13246-13250	mPFC	_
73-22	13251-13254	and	_
73-23	13255-13257	VS	_
73-24	13258-13260	at	_
73-25	13261-13264	age	_
73-26	13265-13267	22	_
73-27	13268-13273	after	_
73-28	13274-13283	adjusting	_
73-29	13284-13287	for	_
73-30	13288-13302	reward-related	_
73-31	13303-13308	brain	_
73-32	13309-13317	function	_
73-33	13318-13320	at	_
73-34	13321-13324	age	_
73-35	13325-13327	20	_
73-36	13328-13331	and	_
73-37	13332-13341	circadian	_
73-38	13342-13352	preference	_
73-39	13353-13355	at	_
73-40	13356-13359	age	_
73-41	13360-13362	22	_
73-42	13363-13364	.	_

74-1	13365-13373	Analyses	_
74-2	13374-13378	were	_
74-3	13379-13388	performed	_
74-4	13389-13399	separately	_
74-5	13400-13403	for	_
74-6	13404-13410	reward	_
74-7	13411-13423	anticipation	_
74-8	13424-13427	and	_
74-9	13428-13431	win	_
74-10	13432-13439	outcome	_
74-11	13440-13449	responses	_
74-12	13450-13451	.	_

75-1	13452-13457	Given	_
75-2	13458-13463	prior	_
75-3	13464-13471	reports	_
75-4	13472-13476	that	_
75-5	13477-13487	depressive	_
75-6	13488-13496	symptoms	_
75-7	13497-13500	are	_
75-8	13501-13511	associated	_
75-9	13512-13516	with	_
75-10	13517-13521	both	_
75-11	13522-13533	eveningness	_
75-12	13534-13537	and	_
75-13	13538-13552	reward-related	_
75-14	13553-13558	brain	_
75-15	13559-13567	function	_
75-16	13568-13569	,	_
75-17	13570-13572	we	_
75-18	13573-13582	initially	_
75-19	13583-13588	added	_
75-20	13589-13592	BDI	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
75-21	13593-13599	scores	_
75-22	13600-13602	at	_
75-23	13603-13606	age	_
75-24	13607-13609	20	_
75-25	13610-13613	and	_
75-26	13614-13616	22	_
75-27	13617-13619	to	_
75-28	13620-13623	the	_
75-29	13624-13633	cross-lag	_
75-30	13634-13640	models	_
75-31	13641-13642	.	_

76-1	13643-13652	Parameter	_
76-2	13653-13662	estimates	_
76-3	13663-13667	were	_
76-4	13668-13677	generated	_
76-5	13678-13681	for	_
76-6	13682-13698	autocorrelations	_
76-7	13699-13700	(	_
76-8	13701-13705	e.g.	_
76-9	13706-13707	,	_
76-10	13708-13720	longitudinal	_
76-11	13721-13725	path	_
76-12	13726-13728	of	_
76-13	13729-13732	one	_
76-14	13733-13741	variable	_
76-15	13742-13744	on	_
76-16	13745-13751	itself	_
76-17	13752-13753	)	_
76-18	13754-13755	,	_
76-19	13756-13765	cross-lag	_
76-20	13766-13779	relationships	_
76-21	13780-13781	(	_
76-22	13782-13786	e.g.	_
76-23	13787-13788	,	_
76-24	13789-13801	longitudinal	_
76-25	13802-13806	path	_
76-26	13807-13809	of	_
76-27	13810-13813	one	_
76-28	13814-13822	variable	_
76-29	13823-13825	on	_
76-30	13826-13833	another	_
76-31	13834-13842	variable	_
76-32	13843-13844	)	_
76-33	13845-13846	,	_
76-34	13847-13850	and	_
76-35	13851-13861	concurrent	_
76-36	13862-13874	correlations	_
76-37	13875-13882	between	_
76-38	13883-13892	variables	_
76-39	13893-13895	at	_
76-40	13896-13900	each	_
76-41	13901-13911	assessment	_
76-42	13912-13917	point	_
76-43	13918-13919	.	_

77-1	13920-13924	This	_
77-2	13925-13930	model	_
77-3	13931-13939	resulted	_
77-4	13940-13942	in	_
77-5	13943-13947	zero	_
77-6	13948-13955	degrees	_
77-7	13956-13958	of	_
77-8	13959-13966	freedom	_
77-9	13967-13968	(	_
77-10	13969-13970	a	_
77-11	13971-13986	just-identified	_
77-12	13987-13992	model	_
77-13	13993-13994	)	_
77-14	13995-13996	,	_
77-15	13997-14006	therefore	_
77-16	14007-14008	,	_
77-17	14009-14024	goodness-of-fit	_
77-18	14025-14030	could	_
77-19	14031-14034	not	_
77-20	14035-14037	be	_
77-21	14038-14047	evaluated	_
77-22	14048-14049	.	_

78-1	14050-14059	Mediation	_
78-2	14060-14068	analyses	_
78-3	14069-14075	tested	_
78-4	14076-14083	whether	_
78-5	14084-14096	associations	_
78-6	14097-14104	between	_
78-7	14105-14114	circadian	_
78-8	14115-14125	preference	_
78-9	14126-14128	at	_
78-10	14129-14132	age	_
78-11	14133-14135	20	_
78-12	14136-14139	and	_
78-13	14140-14149	substance	_
78-14	14150-14161	involvement	_
78-15	14162-14164	at	_
78-16	14165-14168	age	_
78-17	14169-14171	22	_
78-18	14172-14176	were	_
78-19	14177-14185	mediated	_
78-20	14186-14193	through	_
78-21	14194-14208	reward-related	_
78-22	14209-14214	brain	_
78-23	14215-14223	function	_
78-24	14224-14226	in	_
78-25	14227-14230	the	_
78-26	14231-14235	mPFC	_
78-27	14236-14239	and	_
78-28	14240-14242	VS	_
78-29	14243-14245	at	_
78-30	14246-14249	age	_
78-31	14250-14252	22	_
78-32	14253-14254	.	_

79-1	14255-14263	Analyses	_
79-2	14264-14268	were	_
79-3	14269-14278	performed	_
79-4	14279-14289	separately	_
79-5	14290-14293	for	_
79-6	14294-14301	alcohol	_
79-7	14302-14312	dependence	_
79-8	14313-14314	,	_
79-9	14315-14324	frequency	_
79-10	14325-14327	of	_
79-11	14328-14335	alcohol	_
79-12	14336-14339	use	_
79-13	14340-14341	,	_
79-14	14342-14345	and	_
79-15	14346-14355	frequency	_
79-16	14356-14358	of	_
79-17	14359-14367	cannabis	_
79-18	14368-14371	use	_
79-19	14372-14373	.	_

80-1	14374-14383	Parameter	_
80-2	14384-14393	estimates	_
80-3	14394-14398	were	_
80-4	14399-14408	generated	_
80-5	14409-14412	for	_
80-6	14413-14429	autocorrelations	_
80-7	14430-14431	;	_
80-8	14432-14441	cross-lag	_
80-9	14442-14455	relationships	_
80-10	14456-14458	of	_
80-11	14459-14469	endogenous	_
80-12	14470-14473	age	_
80-13	14474-14476	22	_
80-14	14477-14486	variables	_
80-15	14487-14489	on	_
80-16	14490-14493	age	_
80-17	14494-14496	20	_
80-18	14497-14506	circadian	_
80-19	14507-14517	preference	_
80-20	14518-14519	;	_
80-21	14520-14530	concurrent	_
80-22	14531-14543	correlations	_
80-23	14544-14551	between	_
80-24	14552-14556	mPFC	_
80-25	14557-14560	and	_
80-26	14561-14563	VS	_
80-27	14564-14572	response	_
80-28	14573-14575	at	_
80-29	14576-14580	ages	_
80-30	14581-14583	20	_
80-31	14584-14587	and	_
80-32	14588-14590	22	_
80-33	14591-14592	;	_
80-34	14593-14603	concurrent	_
80-35	14604-14616	correlations	_
80-36	14617-14624	between	_
80-37	14625-14634	circadian	_
80-38	14635-14645	preference	_
80-39	14646-14649	and	_
80-40	14650-14659	substance	_
80-41	14660-14671	involvement	_
80-42	14672-14674	at	_
80-43	14675-14678	age	_
80-44	14679-14681	22	_
80-45	14682-14683	;	_
80-46	14684-14687	and	_
80-47	14688-14699	regressions	_
80-48	14700-14702	of	_
80-49	14703-14706	age	_
80-50	14707-14709	22	_
80-51	14710-14719	substance	_
80-52	14720-14731	involvement	_
80-53	14732-14734	on	_
80-54	14735-14745	concurrent	_
80-55	14746-14750	mPFC	_
80-56	14751-14754	and	_
80-57	14755-14757	VS	_
80-58	14758-14766	response	_
80-59	14767-14768	.	_

81-1	14769-14774	Model	_
81-2	14775-14790	goodness-of-fit	_
81-3	14791-14794	was	_
81-4	14795-14804	evaluated	_
81-5	14805-14810	using	_
81-6	14811-14819	absolute	_
81-7	14820-14827	indices	_
81-8	14828-14829	(	_
81-9	14830-14834	i.e.	_
81-10	14835-14836	,	_
81-11	14837-14839	χ2	_
81-12	14840-14841	,	_
81-13	14842-14847	RMSEA	_
81-14	14848-14849	,	_
81-15	14850-14854	SRMR	_
81-16	14855-14856	)	_
81-17	14857-14860	and	_
81-18	14861-14872	comparative	_
81-19	14873-14880	indices	_
81-20	14881-14882	(	_
81-21	14883-14887	i.e.	_
81-22	14888-14889	,	_
81-23	14890-14893	CFI	_
81-24	14894-14895	,	_
81-25	14896-14899	TLI	_
81-26	14900-14901	)	_
81-27	14902-14903	.	_

82-1	14904-14912	Indirect	_
82-2	14913-14920	effects	_
82-3	14921-14925	were	_
82-4	14926-14936	calculated	_
82-5	14937-14942	using	_
82-6	14943-14945	95	_
82-7	14946-14947	%	_
82-8	14948-14958	two-tailed	_
82-9	14959-14960	,	_
82-10	14961-14975	bias-corrected	_
82-11	14976-14985	bootstrap	_
82-12	14986-14996	confidence	_
82-13	14997-15006	intervals	_
82-14	15007-15008	.	_

83-1	15009-15011	In	_
83-2	15012-15020	addition	_
83-3	15021-15022	,	_
83-4	15023-15030	because	_
83-5	15031-15038	smoking	_
83-6	15039-15041	on	_
83-7	15042-15045	the	_
83-8	15046-15049	day	_
83-9	15050-15052	of	_
83-10	15053-15056	the	_
83-11	15057-15061	scan	_
83-12	15062-15065	may	_
83-13	15066-15072	affect	_
83-14	15073-15078	brain	_
83-15	15079-15084	blood	_
83-16	15085-15089	flow	_
83-17	15090-15093	and	_
83-18	15094-15096	is	_
83-19	15097-15107	associated	_
83-20	15108-15112	with	_
83-21	15113-15118	other	_
83-22	15119-15128	substance	_
83-23	15129-15132	use	_
83-24	15133-15134	,	_
83-25	15135-15137	we	_
83-26	15138-15147	performed	_
83-27	15148-15160	supplemental	_
83-28	15161-15169	analyses	_
83-29	15170-15174	that	_
83-30	15175-15183	included	_
83-31	15184-15185	a	_
83-32	15186-15197	dichotomous	_
83-33	15198-15207	indicator	_
83-34	15208-15210	of	_
83-35	15211-15216	daily	_
83-36	15217-15224	smoking	_
83-37	15225-15226	(	_
83-38	15227-15230	yes	_
83-39	15231-15232	,	_
83-40	15233-15235	no	_
83-41	15236-15237	)	_
83-42	15238-15240	as	_
83-43	15241-15242	a	_
83-44	15243-15252	covariate	_
83-45	15253-15255	in	_
83-46	15256-15265	mediation	_
83-47	15266-15274	analyses	_
83-48	15275-15276	.	_

84-1	15277-15286	Including	_
84-2	15287-15290	the	_
84-3	15291-15296	daily	_
84-4	15297-15304	smoking	_
84-5	15305-15314	covariate	_
84-6	15315-15318	did	_
84-7	15319-15322	not	_
84-8	15323-15336	substantially	_
84-9	15337-15342	alter	_
84-10	15343-15346	the	_
84-11	15347-15354	results	_
84-12	15355-15357	of	_
84-13	15358-15367	mediation	_
84-14	15368-15376	analyses	_
84-15	15377-15378	(	_
84-16	15379-15382	see	_
84-17	15383-15390	Figures	_
84-18	15391-15393	S3	_
84-19	15394-15397	and	_
84-20	15398-15400	S4	_
84-21	15401-15403	of	_
84-22	15404-15407	the	_
84-23	15408-15418	Supplement	_
84-24	15419-15420	)	_
84-25	15421-15422	;	_
84-26	15423-15430	results	_
84-27	15431-15438	without	_
84-28	15439-15442	the	_
84-29	15443-15448	daily	_
84-30	15449-15456	smoking	_
84-31	15457-15466	covariate	_
84-32	15467-15470	are	_
84-33	15471-15479	reported	_
84-34	15480-15484	here	_
84-35	15485-15486	.	_

